Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 10:55 ET | Source: World Street Intelligence

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid...